Green Cross Lab Cell Corporation (144510) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Green Cross Lab Cell Corporation KRW 3,740, price KRW 14,050, upside -73.4%, quality 42 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Green Cross Lab Cell Corporation for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. Its main product is Immuncell-LC. GC Cell Corporation has strategic agreement with Lukas Biomedical Co., Ltd. to develop Cell therapy.
Show more
GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. Its main product is Immuncell-LC. GC Cell Corporation has strategic agreement with Lukas Biomedical Co., Ltd. to develop Cell therapy. The company was formerly known as Green Cross Lab Cell Corporation and changed its name to GC Cell Corporation in November 2021. GC Cell Corporation was founded in 2011 and is based in Yongin-si, South Korea.
Stock analysis
Green Cross Lab Cell Corporation (144510) currently trades at 14,050 KRW, while our model-based Fair Value estimate is 3,740 KRW, implying the stock looks roughly 275.7% overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of 8,310 KRW per share, and 0 of the 12 models we run sit above the 14,050 KRW price.
Bear case: the Dividend Discount group reads lowest at 1,106 KRW, and 12 of the 12 models stay below the price. Evidence for this calculation is medium.
Scenario range: 2,781 KRW (bear) to 5,312 KRW (bull), the price of 14,050 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Green Cross Lab Cell Corporation reported revenue of 166B KRW in FY2025 versus 168B KRW in FY2021, a compound −0.4%/yr. Reported net income was −273B KRW in FY2025.
Key figures
Market cap 211B KRW (≈ $155M) · P/S ratio 3.62 · Dividend yield 0.8% · Net margin −1.2% · Return on equity −1.3% · Return on assets (EBIT) −0.7% · Operating margin −13.7% · Revenue growth (YoY) −5.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).
What moves the price
The share trades about 49% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −73%, 144510 screens richer than that median.
Fair Value models
Bear 2,781 KRWFair Value 3,740 KRWBull 5,312 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−5.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−11.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.1%
Start year 2020 (pandemic). Over 10 years: +17.0% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.0%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
7.5% (2020) → −8.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+55.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +51.9% a year for the price.
Compare Green Cross Lab Cell Corporation with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 143 stocks
Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score42 · Below median
Fair Value upside−73% · Bottom 25%
Profitability
Return on assets−2% · Below median
Net margin (TTM)−1% · Below median
Operating margin (TTM)−14% · Bottom 25%
Growth and dividend
Revenue growth−6% · Below median
Dividend yield (TTM)0.8% · Below median
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
P/FCF0.1× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 28
PAST (return on equity)0· sector 8
HEALTH (low debt)100· sector 95
DIVIDEND (yield)16· sector 30
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Green Cross Lab Cell Corporation (144510) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 3,740 KRW versus a price of 14,050 KRW, about −73% upside (overvalued).
What is the fair value of 144510?
Our model-based fair value for Green Cross Lab Cell Corporation is 3,740 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 14,050 KRW.
What is the quality score of 144510?
Green Cross Lab Cell Corporation has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Green Cross Lab Cell Corporation (144510)?
Our model-based price target is the fair value of 3,740 KRW (as of Sep 24, 2026) from 12 valuation models. Cautious scenario 2,781 KRW, optimistic scenario 5,312 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Green Cross Lab Cell Corporation stock forecast for 2026?
Our models put fair value at 3,740 KRW, about −73% upside versus a price of 14,050 KRW (overvalued). Cautious scenario 2,781 KRW, optimistic scenario 5,312 KRW. The calculation is refreshed regularly with new filings.
Does Green Cross Lab Cell Corporation pay a dividend?
Green Cross Lab Cell Corporation currently shows a dividend yield of about 0.78% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Green Cross Lab Cell Corporation (144510)?
For today's price to be fair in a discounted-cash-flow model, Green Cross Lab Cell Corporation would have to grow free cash flow by +55.1 % per year for five years (discount rate 14.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +14.1 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 144510 use?
Our models discount Green Cross Lab Cell Corporation at 14.8 %: a base by market capitalisation (micro), damped by beta 1.51, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Green Cross Lab Cell Corporation that is +55.1 % per year a year over ten years, using the same discount rate (14.8 %) and the same formula as our fair value.
How much growth has Green Cross Lab Cell Corporation (144510) delivered so far?
Over the past 5 years revenue at Green Cross Lab Cell Corporation grew +14.1 % a year. The price currently implies +55.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Green Cross Lab Cell Corporation (144510) growing?
The median revenue growth in the sector is +1.9 % a year. That is the yardstick for the growth priced into Green Cross Lab Cell Corporation (+55.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Green Cross Lab Cell Corporation (144510)?
The free-cash-flow yield on the price is 1.29 %: that much free cash flow Green Cross Lab Cell Corporation produces per unit of market value. When it exceeds the discount rate of our models (14.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Green Cross Lab Cell Corporation (144510)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Green Cross Lab Cell Corporation it is 3,740 KRW per share (as of Sep 24, 2026), against a price of 14,050 KRW. It is the blended result of 12 valuation models (cash flow, earnings, asset, dividend).
Is Green Cross Lab Cell Corporation stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 144510 trades above its calculated fair value: price 14,050 KRW, fair value 3,740 KRW, a gap of about −73% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 144510?
No. The price is what the market pays today (14,050 KRW); the fair value is what the company's own numbers justify (3,740 KRW). For Green Cross Lab Cell Corporation the two are 10,310 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Green Cross Lab Cell Corporation worth?
The market values Green Cross Lab Cell Corporation at about 211B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 14,050 KRW; our models calculate a fair value of 3,740 KRW per share.
What do the bullish and bearish scenarios say about 144510?
Our models span a range for Green Cross Lab Cell Corporation: cautious scenario 2,781 KRW, base 3,740 KRW, optimistic 5,312 KRW per share (as of Sep 24, 2026, price 14,050 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Green Cross Lab Cell Corporation (144510)?
Balance-sheet figures for Green Cross Lab Cell Corporation (as of Sep 24, 2026): return on equity −1.3%. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is 144510 from its 52-week high?
Green Cross Lab Cell Corporation trades at 14,050 KRW, about 49% below its 52-week high of 27,500 KRW and 11% above the low of 12,710 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 3,740 KRW is for.
Which stocks are comparable to Green Cross Lab Cell Corporation?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Green Cross Lab Cell Corporation stock attractive at the current price?
The data as of Sep 24, 2026: price 14,050 KRW, calculated fair value 3,740 KRW (−73%), Quality Score 42/100, from 12 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 144510 calculated?
We run Green Cross Lab Cell Corporation through 12 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 3,740 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Green Cross Lab Cell Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Green Cross Lab Cell Corporation (144510)?
The closing price on Sep 23, 2026 was 14,050 KRW. Our model-based fair value is 3,740 KRW, about −73% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Green Cross Lab Cell Corporation right now?
The price sits above even our optimistic bull case (5,312 KRW). The favourable scenario is already priced in. Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (2,781 KRW to 5,312 KRW) leaves room in how you read the outcome.
Key figures of Green Cross Lab Cell Corporation
How large is the market capitalisation of Green Cross Lab Cell Corporation (144510)?
The market capitalisation of Green Cross Lab Cell Corporation is 211B KRW (≈ $155M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Green Cross Lab Cell Corporation (144510)?
The price-to-sales ratio of Green Cross Lab Cell Corporation is 3.62 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Green Cross Lab Cell Corporation (144510)?
The dividend yield of Green Cross Lab Cell Corporation is 0.8%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Green Cross Lab Cell Corporation (144510)?
The net margin of Green Cross Lab Cell Corporation is −1.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Green Cross Lab Cell Corporation (144510)?
The return on equity (ROE) of Green Cross Lab Cell Corporation is −1.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Green Cross Lab Cell Corporation (144510)?
On an EBIT basis the return on assets of Green Cross Lab Cell Corporation is −0.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Green Cross Lab Cell Corporation (144510)?
The operating margin of Green Cross Lab Cell Corporation is −13.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Green Cross Lab Cell Corporation (144510)?
Revenue at Green Cross Lab Cell Corporation is growing −5.5% versus a year earlier (3y avg −11.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Green Cross Lab Cell Corporation (144510)?
Earnings per share at Green Cross Lab Cell Corporation are growing −47.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Green Cross Lab Cell Corporation (144510) carry?
The net debt of Green Cross Lab Cell Corporation is 50.1B KRW (fiscal year 2025, ≈ 18.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Green Cross Lab Cell Corporation in the live analysis
One click puts Green Cross Lab Cell Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
